gujral fcm 2

128
Flow Cytometry – Principles and Applications Second Basic Hematopathology Course TMH June 11-12, 2011 Dr Sumeet Gujral, MD Associate Professor Department of Pathology Tata Memorial Hospital, Mumbai [email protected]

Upload: candiddreams

Post on 21-Jul-2016

16 views

Category:

Documents


2 download

DESCRIPTION

TMH proceedings 2010-2011,pdf

TRANSCRIPT

Page 1: Gujral FCM 2

Flow Cytometry – Principles and Applications

Second Basic Hematopathology CourseTMHJune 11-12, 2011

Dr Sumeet Gujral, MDAssociate ProfessorDepartment of PathologyTata Memorial Hospital, [email protected]

Page 2: Gujral FCM 2

Role of a Hematopathologist

• Establishing Diagnosis

• Prognostication (sub-classification)

• Prediction

• Evaluation of treatment effectiveness (MRD)

Page 3: Gujral FCM 2

Leukemia/Lymphoma - Diagnosis

• Clinical: History and Examination

• Routine investigations

• Morphology (smear, biopsy)

• Ancillary techniques

Page 4: Gujral FCM 2

Ancillary techniques

• Immunohistochemistry, • Flow Cytometry, • Cytogenetics, • Molecular Diagnostics

• Diagnostic• Prognostic• Predictive

Page 5: Gujral FCM 2

100bpladder

1 2 3 4 5 6

RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) detects diagnostic translocation markers like BCR/ABL in CML - BCR/ABL: b3a2 437bp

Page 6: Gujral FCM 2

Flow Cytometry

Page 7: Gujral FCM 2

Localization of antigens or proteins in cells using labeled antibodies through antigen-antibody interactions,

Reaction visualized by a marker (fluorescent dye, enzyme, colloidal gold etc)

Immunophenotyping

Page 8: Gujral FCM 2

Complementary

FCMmulticolor immunophenotypingfluids

Immunohistochemistry mostly single colorbiopsy

Page 9: Gujral FCM 2

Our practice

Flow cytometry – Liquid and Solid

Immunohistochemistry – Solid and Liquid

Page 10: Gujral FCM 2

flow + cyto + metry

• 1953 - The first impedance-based flow cytometry device, using the coulter principle (Wallace A Coulter)

• 1968 - The first fluorescence-based flow cytometry device (ICP 11) by Wolfgang Göhde, University of Munster

Page 11: Gujral FCM 2

It is the measurement of cellular properties as cells move in a fluid stream (flow), past a stationary set of detectors (thousand events per second)

Technique of quantitative single cell analysis

Principle

It analyses - physical, and - chemical properties (immunofluorescence) of cell

Page 12: Gujral FCM 2

Components of a Flow Cytometer

• Fluidics: a flow cell with sheath fluid (hydrodynamic focussing)

• Optics: LASERS, single wavelength,

coherent light (however incoherent light is of random phase varying with time and position)

• a detector and Analogue-to-Digital Conversion (ADC) system - which generates FSC and SSC as well as fluorescence signals from light into electrical signals that can be processed by a computer

• an amplification system – linear or

logarithmic

• a computer for analysis of the signals- Single or multiple Lasers- Sorter

Page 13: Gujral FCM 2

Types

- Single Laser or Multiple Lasers(1 laser three color, 4 lasers 18 fluorescence detectors)

- Sorter (so as to purify populations of interest )

- Laser scanning cytometers

Page 14: Gujral FCM 2

Advantages of a FCM

• Study of cells, chromosomes and particles (analysis, counting and sorting)

• Thousand of particles per second

• Multiparametric analysis at a single cell level

• Pattern studies

• Sorting

Page 15: Gujral FCM 2

Research Applications• Autofluorescent Proteins • Antigen or Ligand Density • Apoptosis • Enzyme activity • DNA, RNA content and changes in the cell cycle • Membrane Potential • Cytokine receptors and it's synthesis • Drug uptake and efflux • Phagocytosis • Viability • Changes in Intracellular pH • Changes in Intracellular calcium • Changes in Intracellular glutathione • Changes in Oxidative Burst

Page 16: Gujral FCM 2

Diagnostic Applications

1. Monitoring AIDS patients 2. Immunophenotyping: Diagnosis, subtyping and

prognostication of hematolymphoid malignancies3. Monitoring Minimal Residual Disease 4. Determining CD34 counts5. Reticulocyte Counts 6. Diagnosis of PNH 7. DNA analysis of S-phase fraction8. Platelet counts

Page 17: Gujral FCM 2

It requires a suspension of single cells No information on tissue architecture

Expensive, maintenance

Shortcomings of a FCM

Page 18: Gujral FCM 2

ImmunophenotypingSampleProcessAcquireAnalysisFinal report

Page 19: Gujral FCM 2

Flow cycle

Referring physician Sample collection/transportation

Preparation of cells of interest Add antibodies tagged with fluorochromes

Acquire (flow) the cells LASER

Amplified signals Digitized

Analyze Report Referring physician

Page 20: Gujral FCM 2

Antigen expression:RBCs, WBCs, Platelets, Others

CD3

Cyto CD3

Tdt

Page 21: Gujral FCM 2

Lysis of red cells

Add reagents

Process

Page 22: Gujral FCM 2

Intracellular staining

For Intracellular staining, cells are first fixed in suspension and then permeabilised before adding the fluorochrome

This allows probes to access intracellular structures while leaving the morphological scatter characteristics of the cells intact

Commercial kits/In-house

Page 23: Gujral FCM 2

Cells are fixed – permeabilised –add antibody (FL)

CD3

Cyto CD3

Tdt

Page 24: Gujral FCM 2

Results

Page 25: Gujral FCM 2

Physical Properties Scatter pattern, FSC vs SSC

Forward - Size

Side - Granularity

Note: no RBCs

Page 26: Gujral FCM 2

Chemical propertiesImmunofluoresence

Page 27: Gujral FCM 2

How do we select cells of interest?Gating

Page 28: Gujral FCM 2

Scatter pattern, FSC vs SSC

Forward - Size

Side - Granularity

Page 29: Gujral FCM 2

Cells of interest: FSC vs SSC

Forward - Size

Side - Granularity

Page 30: Gujral FCM 2

FSC vs SSC CD45 Gating CD19 Gating

Cells of interest may be scanty

Page 31: Gujral FCM 2

CD - 23391 INDULKAR (BM).003

FSC - HeightS

SC

- H

eig

ht

0 256 512 768 10240

256

512

768

1024

CD - 23391 INDULKAR (BM).003

CD19 - PE

SS

C -

Heig

ht

100 101 102 103 1040

256

512

768

1024

CD - 23391 INDULKAR (BM).003

CD3 - PerCP

SSC

- H

eigh

t

100 101 102 103 1040

256

512

768

1024

FSC vs SSC

Study B-cellsStudy T-cells

T and B cells

Page 32: Gujral FCM 2

CD - 23391 INDULKAR (BM).003

FSC - Height

SS

C -

Hei

ght

0 256 512 768 10240

256

512

768

1024

GatingSmall cell Lymphoma

Page 33: Gujral FCM 2

What is CD45 gating?

How is CD45 gating better than SSC/FSC gating in Acute Leukemia?

Page 34: Gujral FCM 2

Importance of CD45 gating when blasts are few

Guess

Page 35: Gujral FCM 2

CD45 gating means CD45 in each tube

CD45

Myeloid tube T cell tube B cell tube MDS tube Other tube

CD45 CD45 CD45CD45

Page 36: Gujral FCM 2

Generally 3-6 tubes,How to select antibody combinations?

Page 37: Gujral FCM 2

CD3 - FITCCD19 - PE CD13 – PerCPCD45 – TR

Four color means a cocktail of four antibodies

CD3 - FITCCD4 - PE CD8 – PerCPCD45 – TR

or of same lineage..

of different lineages..

Page 38: Gujral FCM 2

Expression of myeloid antigens – 6 colors

CD117APC

CD11bPECy7

CD15FITC

CD45APC Cy7

CD13PECD16PECy5

CD13 FITC

Page 39: Gujral FCM 2

Indian Guidelines, 2008

Most labs still do 3-4 colors (single Laser)

Page 40: Gujral FCM 2

10 antibodies plus controls for Acute Leukemia

9 antibodies plus controls for CLPD

Published minimal panels may be INADEQUATE

Recommendations

IJPM, 2008

Page 41: Gujral FCM 2

All lymphoid cells CD45+ (LCA)

B-cells CD19, CD10, CD20, CD23, FMC7, k/l LC, cCD22

T-cells CD3, CD4, CD5, CD7, CD8, cCD3

Myeloid cells CD13, CD33, CD117, anti MPO

Megakaryocytic CD41, CD61

Blasts CD34, Tdt, CD99, HLADR

Others: CD1a, CD2, CD11c, CD15, CD16, CD25, CD38, CD43, CD56,CD55, CD59 CD64, CD79a, CD103, CD138, TCR alpha/beta, TCRgamma/delta, IgM, IgD

Cytometry B Clin Cytom. 2009 May;76(3):199-205

Page 42: Gujral FCM 2

6 color and more

Page 43: Gujral FCM 2

CD23APC

CD5PECy7

Lambda FITC

CD19APC H7

Kappa PECD20PerCpCy5.5

Lambda FITC

Single color 6 color, all B cell lineage

Page 44: Gujral FCM 2

Normal 6 color pattern with T and B cell markers

Multiple gates

Page 45: Gujral FCM 2

Normal 6 color pattern with T and B cell markers

Page 46: Gujral FCM 2

Colors unstoppable…

• Euroflow - 8 colors

• Brentwood et al - 10 colors

• Roederer et al - 15 colors

• Most labs do 3-4 color IPT

Page 47: Gujral FCM 2

In Immunophenotyping, FCM helps in detecting following:

- presence or absence of an antigen- intensity- blasts- Clonality: LCR, V-beta repertoire- scanty cells, Maturation patterns

CD3 antibody by FCM detects the fully assembled TCR-CD3 complex, which is present on the surface of T cells only.

In contrast, the CD3 IHC stain usually detects only the epsilon component of CD3, therefore cannot distinguish between T & NK cells.

Page 48: Gujral FCM 2

Diagnosis of Leukemia/lymphoma

• Morphology H&E stain - BiopsyGiemsa stain – Aspirate

• Cytochemistry (MPO, NSE)

• Immunohistochemistry, Flow cytometry

• Cytogenetics, FISH

• Molecular methods

Page 49: Gujral FCM 2

Case

Page 50: Gujral FCM 2

55 year old male

Bilateral cervical and axillary lymph nodes

Normal Complete Blood Counts

Page 51: Gujral FCM 2

Provisional diagnosis: LymphomaAdvise: Biopsy diagnosisFNAC and flow

Page 52: Gujral FCM 2

3 color panel

Page 53: Gujral FCM 2

3 color panel

Page 54: Gujral FCM 2

CD45, CD20, CD19, CD5, CD23, CD22wk, CD20, Kappa LC, CD200

Impression: B-cell lymphoma, SLL

Prognostic markers: CD38, ZAP70

3 color panel

Page 55: Gujral FCM 2

CD19 gating

Same patient of CLL, however, CD19 gating was done

4 color panel

Page 56: Gujral FCM 2

B-CLPD – 6 color panel

Debris

Page 57: Gujral FCM 2

B-CLPD – 6 color panel

CD45, CD20, CD19, CD5, CD23, CD22wk, CD20, Kappa

LC, CD200

Impression: B-cell lymphoma, SLL

Page 58: Gujral FCM 2

Subtyping of Small B cell lymphomas

Page 59: Gujral FCM 2

Patterns recognition

• MDS• Hematogones

Page 60: Gujral FCM 2

Normal BM Maturation patterns of myeloid / monocytic cells

Page 61: Gujral FCM 2

NeutrophilsCD13+, CD16+

Page 62: Gujral FCM 2

NeutrophilsCD11b+, CD117-

Page 63: Gujral FCM 2

B-cell maturation

Cyto muheavy chain

IgM+, IgD+CD5+

IgM

IgG IgA

CD10, BCL6+

Pax5 (My+)

CD79a (T+)

IgG,A,M.D.EIgMIgM

BCR

Page 64: Gujral FCM 2

T-cell maturation

Prothymocyte Subcapsular Th Cortical Th Medullary Th PTC

CD7

Tdt

CD1a

CD2/CD5

CD3

CD4/CD8

surface

DPT CD4+

CD8+

cytoplasmic

Page 65: Gujral FCM 2

Myelodysplastic syndrome

Page 66: Gujral FCM 2
Page 67: Gujral FCM 2
Page 68: Gujral FCM 2
Page 69: Gujral FCM 2
Page 70: Gujral FCM 2

MDS Scatter pattern and maturation pattern

• FSC versus SSC• Myeloid cells: CD11c, CD13, CD15, CD16• Monocytic: CD33, CD56, CD14• Erythroid: CD235, CD71• Megakaryocytic: CD41, CD61, Morphology

Page 71: Gujral FCM 2

Normal MDS

Patterns of antigen expression - Granulocytic maturation

FSC vs SSC

Page 72: Gujral FCM 2

Patterns of antigen expression - Granulocytic maturation

CD45 vs SSC

Normal MDSCD13 CD16CD11c CD16

Page 73: Gujral FCM 2

Normally Maturing Granulocytes

Sickle/Concave pattern Wave pattern

Page 74: Gujral FCM 2

Granulocytic maturation in MDS (CD13 vs CD16)

NORMAL MDS

Normal MDS

Page 75: Gujral FCM 2

Granulocytic maturation in MDS (CD11C vs CD16)

NORMAL MDS

Normal MDS

Page 76: Gujral FCM 2

Hematogones

Page 77: Gujral FCM 2

Hematogones

medium sized lymphoid cells,scant cytoplasm, round to irregular nuclei, dense homogeneous chromatin no - very small nucleoli

Page 78: Gujral FCM 2

Bone marrow from a 3-year-old boy with megakaryocytic thrombocytopenia. Hematogones bear close resemblance to the neoplastic lymphoblasts

Numerous lymphoblasts are present in this bone marrow smear from a 5-year-old girl with precursor B-ALL

Page 79: Gujral FCM 2
Page 80: Gujral FCM 2

Hematogones B-cell ALL

Page 81: Gujral FCM 2

Another case

Page 82: Gujral FCM 2

CD19+, CD10+, FMC7+, CD79b+, CD38+, LLC+ CD3-, CD5-, CD23-, KLC -

Diagnosis: High grade B cell lymphoma

Pleural fluid, lymphoid rich effusion

Page 83: Gujral FCM 2

CD10+, CD19+, HLADR+

B cell ALL, Burkitt’s Lymphoma

Page 84: Gujral FCM 2

CD10+, CD19+, HLADR+

FL, DLBCL

B cell ALL, Burkitt’s Lymphoma

Page 85: Gujral FCM 2

CD10+, CD19+, HLADR+

FL, DLBCL

Hematogones(Tdt+/-)

B cell ALL, Burkitt’s Lymphoma

Page 86: Gujral FCM 2

Lymph node FNAC and FCM

Lymph node Biopsy and FCM

Page 87: Gujral FCM 2

Primary folliclesIgM+ IgD+

Secondary follicles, IgD-

Mantle zoneIgM+ IgD+

Page 88: Gujral FCM 2
Page 89: Gujral FCM 2
Page 90: Gujral FCM 2

B cell clonalitySmall B cell lymphomas

Page 91: Gujral FCM 2

CD20+

Page 92: Gujral FCM 2

Brent Wood et al

?? Role of FCM

Page 93: Gujral FCM 2

Follicular lymphoma , Grade 1 Follicular hyperplasia

Page 94: Gujral FCM 2

FL (Grade 3) Reactive

Bcl2 might not help

flow flow flow

Page 95: Gujral FCM 2

Light chain restriction

CD20 and lambda

Page 96: Gujral FCM 2

Quantitation by FCM

Page 97: Gujral FCM 2

Platelet counts

Various method

Page 98: Gujral FCM 2

International Flow Reference Method

RBC/Platelet Ratio Method (Dual Platform Method)

Absolute Platelet Count=

RBCevents X RBC count Platelet events (Automated Cell Analyzer)

ISLH Task Force, Am J Clin Pathol 115, 460-464.(2001)

CD41/61

RBC

Platelets

Page 99: Gujral FCM 2

Single Platform Immunoplatelet method

Single Platform Bead Assay

Absolute platelet count =

Gated Plt events X Bead count Gated bead events (fixed value)

PlateletsBead

s

Sehgal K, Cytomerty B, Clinical Cytometry, 2010

Page 100: Gujral FCM 2

Lymphocyte subset analysis

CD4/CD8 Counts

Page 101: Gujral FCM 2

Lymphocyte subset analysis

Page 102: Gujral FCM 2

Normal peripheral blood

CD4 PE

CD8FITC

Page 103: Gujral FCM 2

PNH studies (WBCs and RBCs)

It is a rare clonal stem cell disorder of hematopoietic cells that is associated with intravascular hemolysis, venous thrombosis, and cytopenias related to bone marrow aplasia.

Somatic mutations of PIGA gene

Loss of GPI (CD55, CD59)

FLAER test: In vitro binding of a fluorescent-labeled modified toxin that is dependent on the presence of GPI anchors.

Page 104: Gujral FCM 2

Normal Neutrophils

Abnormal Neutrophils

Page 105: Gujral FCM 2

CD34 stem cells enumeration

Page 106: Gujral FCM 2

ISHAGE protocol

Dual Platform - Lyse wash method

Performed in duplicate

Acquire at least 100 CD34+ events for an intra assay C.V of 10%

Four parameters are used– FSC– SSC – Intensity of CD34 staining– Intensity of CD45 staining

All initial ungated events must be acquired and isotype controlsare not required

Then analyzed in a sequential manner (BOOLEAN gating)as per the ISHAGE protocol

Page 107: Gujral FCM 2

Isotype controls are not required with ISHAGE gating system

CD34 % =G4/G1 x100

Absolute CD34=CD34% X WBC 100

N=CD34+ events in R4

D=CD45+ events in R1

Page 108: Gujral FCM 2

ISHAGE Single Platform

Subtract 7AAD + cells from R1

R7=bead events

Lyse no wash processing

Reverse pipetting is essential

Page 109: Gujral FCM 2

Reticulocyte counts

DNA Ploidy

FCM studies cell surface antigens (phenotype), DNA content (ploidy) (DNA index) and DNA flow cytometric proliferation analysis (S-phase fraction or %S-phase).  

Page 110: Gujral FCM 2

Minimal residual disease in ALL

(eg., MRD Lite)

Page 111: Gujral FCM 2

5-year-old boy presented with fever - 1 month

On examination: Pallor, Hepatosplenomegaly

Complete Blood CountsHb - 6gm%TLC – 44,000/cmmPlatelets – 1.25lakh/cmm

Peripheral Blood Smear Examination

Page 112: Gujral FCM 2

DiagnosisMPO, NSE negative

Page 113: Gujral FCM 2

MPO negative NSE negative

Diagnosis

Page 114: Gujral FCM 2

3 Color FCM

FSC vs SSC

Blasts only

Page 115: Gujral FCM 2
Page 116: Gujral FCM 2

CD19, CD10, HLADR positive blasts

CD34 negative

Diagnosis: B-cell ALL

Page 117: Gujral FCM 2

Morphological differentials CD19, CD10, HLADR positive blasts

1. B-cell ALL Tdt, CD34

2. Burkitt’s Lymphoma Kappa, Lambda

Page 118: Gujral FCM 2

LymphocytosisCD10+, CD19+, HLADR+, Tdt+

B cell ALL Hematogones

Page 119: Gujral FCM 2

Diagnosis: Tdt + B-cell ALL

Prognostication: Cytogenetic studies

Chemotherapy: MCP 841 protocol

Evaluation of Treatment: Day 18 BM

- Morphology

- MRD Lite by flow

Page 120: Gujral FCM 2

Day 18 post induction

Page 121: Gujral FCM 2

MRD lite

• Hypothesis: Day 18 post induction, no hematogones in BM

• CD19, HLADR, CD34, syto 13

Page 122: Gujral FCM 2

MRD Tube

FSC-AF

SC

-H0 256 512 768 1024

0

256

512

768

1024

Gate 1

MRD Tube

FSC-A

SS

C-A

0 256 512 768 10240

256

512

768

1024

Gate 2

MRD Tube

CD10 PE-A

CD

19 A

PC

-A

100

101

102

103

104

100

101

102

103

104

Gate3

MRD Tube

KAPPA/LAMBDA FITC-A

CD

34 P

erC

P-A

100

101

102

103

10410

0

101

102

103

104

Gate 4MRD Tube

CD34 PerCP-A

CD

19 A

PC

-A

100

101

102

103

10410

0

101

102

103

104 MRD Tube

CD10 PE-A

CD

19 A

PC

-A

100

101

102

103

104

100

101

102

103

104

MRD Tube

KAPPA/LAMBDA FITC-A

CD

19 A

PC

-A

100

101

102

103

104

100

101

102

103

104 MRD Tube

CD10 PE-W

SS

C-A

0 256 512 768 10240

256

512

768

1024MRD Tube

CD19 APC-A

SS

C-A

100

101

102

103

104

0

256

512

768

1024

Gate 5

FCS Filename Gate # of Events % of Gated Cells

% of All Cells

1,3a,100_MRD TUBE.fcs

None 104464 100.0 44.75

1,3a,100_MRD TUBE.fcs

Gate 1 104464 100.0 44.75

1,3a,100_MRD TUBE.fcs

Gate 2 58041 55.56 24.86

1,3a,100_MRD TUBE.fcs

Gate3 1157 1.11 0.5

1,3a,100_MRD TUBE.fcs

Gate 4 1126 1.08 0.48

1,3a,100_MRD TUBE.fcs

Gate 5 6481 6.2 2.78

1,3a,100_MRD TUBE.fcs

Gate6 12102 11.58 5.18

1 in 100 tumor cell dilution – MRD Tube

MRD = 1.43%

Page 123: Gujral FCM 2

Quality control

Page 124: Gujral FCM 2

• Instrument quality controlExperiment setup includes:

- PMT Voltage setup

- Compensation setup and

- Titration of Antibodies

• Reagent/Antibody quality control

• Process quality control

• Tandem dyes

• Trained staff, CMEs

Page 125: Gujral FCM 2

For Referring Oncologist/Pathologist

Indications of FCM, short cuts

Transportation/viability of sample

Multicolor analysis and reading the report

Page 126: Gujral FCM 2

QC - Final comprehensive report

• Morphology• Flow cytometry / IHC• Cytogenetics• Molecular Diagnostics

Page 127: Gujral FCM 2
Page 128: Gujral FCM 2